AGP Executive Report
Last update: 6 hours agoBiotech: Europe approved Zealand Pharma’s twice-weekly treatment for adults with short bowel syndrome, a notable new option for patients. Iceland-based Alvotech, meanwhile, reported nine-month revenue of $323.4 million, down from $420 million a year earlier, while adjusted EBITDA rose to $78.3 million. Data Centres and Energy: Iceland is tightening power availability for data centres as hydro and geothermal capacity comes under pressure. At an Arctic industry panel, Icelandic startup Hringvarmi argued for capturing data-centre waste heat to grow food, highlighting one way to reduce local costs. Cancer Treatment: European regulators recommended belzutifan with lenvatinib for advanced kidney cancer after prior immunotherapy; the European Commission’s decision will also cover Iceland, with a ruling expected within two months.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
